Suchergebnisse - "Tantravahi, Srinivas K"

PubPharm (3)

1

Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE) : a post-hoc analysis of molecular biomarkers in a phase 2 study

enthalten in: The Lancet. Haematology | 2022

von Pemmaraju, N. | Garcia, J. | Potluri, J. | +7

CommentIn: Lancet Haematol. 2022 Jun;9(6):e391-e392. - PMID 35576959

2

Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response : Phase II Safety and Efficacy

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Harrison, C. | Garcia, J. | Somervaille, T. | +16

CommentIn: J Clin Oncol. 2022 May 20;40(15):1693-1695. - PMID 35319999

3

A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia

enthalten in: Leukemia & lymphoma | 2016

von Tantravahi, S. | Szankasi, P. | Khorashad, J. | +4

1
[1]